Temporal trends and demographic disparities in myelodysplastic syndrome-associated mortality in Acute Myeloid Leukemia patients in the United States: A population-based analysis (1999–2023)
Population-based analysis shows significant mortality disparities in acute myeloid leukemia patients with myelodysplastic syndromes, highlighting urgent public health needs.
Key Points
To analyze trends in mortality among patients with acute myeloid leukemia and myelodysplastic syndromes in the U.S.
Identified AML and MDS cases from the CDC WONDER database
Calculated age-adjusted mortality rates (AAMR)
Used Joinpoint regression for trend assessment
Applied ARIMA models for future projections
17,387 deaths attributed to MDS and AML in the U.S. from 1999 to 2023
AAMR decreased by 15.6% from 14.7 to 12.4 per million
Males experienced a higher mortality burden compared to females, nearly twice as high in 2023
Racial disparities persist with higher mortality among Black individuals compared to other races